当代肝硬化患者队列中肝细胞癌的危险因素
研究基于美国两个当代前瞻性多族裔肝硬化队列(2733例),随访7406人年,135例发生肝细胞癌,年发病率1.82%。治愈丙肝、酒精性肝病和NAFLD肝硬化年发病率分别为1.71%、1.32%和1.24%;治愈丙肝较NAFLD进展为肝癌风险高2倍(HR 2.04)。当前吸烟和超重/肥胖亦与肝癌风险相关。
要点
- 肝硬化患者肝癌年发病率为1.82%(95%CI 1.51-2.13)。
- 治愈丙肝肝硬化患者肝癌风险是NAFLD肝硬化的2倍(HR 2.04)。
- 当前吸烟(HR 1.63)和超重/肥胖(HR 1.79)与肝癌风险相关。
核心结论
- 肝硬化患者肝癌发病率低于既往报道,且风险因病因不同而异,丙肝肝硬化风险较高,NAFLD肝硬化风险较低。
- 当前吸烟和超重/肥胖在各病因中均增加肝癌风险。
研究设计与样本
- 研究使用两个当代前瞻性多族裔肝硬化患者队列:Texas Hepatocellular Carcinoma Consortium Cohort和Houston Veterans Administration Cirrhosis Surveillance Cohort。
- 患者来自美国七个中心,随访至肝癌诊断、移植、死亡或2021年6月30日。
- 共纳入2733例肝硬化患者(平均年龄60.1岁,女性31.3%)。
主要发现
- 入组时19.0%有活动性HCV,23.3%有治愈HCV,16.1%有酒精性肝病,30.1%有NAFLD。
- 随访7406人年期间,135例发生肝癌,年发病率为1.82%(95%CI 1.51-2.13)。
- 治愈HCV患者肝癌年发病率为1.71%,酒精性肝病患者为1.32%,NAFLD肝硬化患者为1.24%。
- 与NAFLD相比,治愈HCV患者进展为肝癌的风险高2倍(HR 2.04;95%CI 1.24-3.35)。
- 当前吸烟(HR 1.63;95%CI 1.01-2.63)和超重/肥胖(HR 1.79;95%CI 1.08-2.95)也与肝癌风险相关。
关键数值与推荐
- 肝硬化患者肝癌年发病率为1.82%(95%CI 1.51-2.13)。
- 治愈HCV患者肝癌年发病率为1.71%,酒精性肝病患者为1.32%,NAFLD肝硬化患者为1.24%。
- 治愈HCV vs NAFLD的肝癌风险HR为2.04(95%CI 1.24-3.35)。
- 当前吸烟的肝癌风险HR为1.63(95%CI 1.01-2.63)。
- 超重/肥胖的肝癌风险HR为1.79(95%CI 1.08-2.95)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Etiological risk factors for cirrhosis have changed in the last decade. It remains unclear to what extent these trends in cirrhosis risk factors have changed HCC risk. APPROACH AND RESULTS: We used data from two contemporary, prospective multiethnic cohorts of patients with cirrhosis: the Texas Hepatocellular Carcinoma Consortium Cohort and the Houston Veterans Administration Cirrhosis Surveillance Cohort. Patients with cirrhosis were enrolled from seven US centers and followed until HCC diagnosis, transplant, death, or June 30, 2021. We calculated the annual incidence rates for HCC and examined the effects of etiology, demographic, clinical, and lifestyle factors on the risk of HCC. We included 2733 patients with cirrhosis (mean age 60.1 years, 31.3% women). At enrollment, 19.0% had active HCV, 23.3% had cured HCV, 16.1% had alcoholic liver disease, and 30.1% had NAFLD. During 7406 person-years of follow-up, 135 patients developed HCC at an annual incidence rate of 1.82% (95% CI, 1.51-2.13). The annual HCC incidence rate was 1.71% in patients with cured HCV, 1.32% in patients with alcoholic liver disease, and 1.24% in patients with NAFLD cirrhosis. Compared to patients with NAFLD, the risk of progression to HCC was 2-fold higher in patients with cured HCV (HR, 2.04; 95% CI, 1.24-3.35). Current smoking (HR, 1.63; 95% CI, 1.01-2.63) and overweight/obesity (HR, 1.79; 95% CI, 1.08-2.95) were also associated with HCC risk. CONCLUSIONS: HCC incidence among patients with cirrhosis was lower than previously reported. HCC risk was variable across etiologies, with higher risk in patients with HCV cirrhosis and lower risk in those with NAFLD cirrhosis. Current smoking and overweight/obesity increased HCC risk across etiologies.
引用
- Kanwal F, Khaderi S, Singal AG, et al. Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology. 2023. PMID: 35229329. doi:10.1002/hep.32434
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。